This Custom Synthesis Stock Rises 42% in 1 Year: Peptides, CMS Orders and One Concentration Question

A custom synthesis stock on the NSE has climbed around 42% in twelve months, by a rough route. The custom synthesis stock closed at Rs 16,156 on 17 September 2025 and Rs 22,860 on 17 September 2026. In between it fell to Rs 11,500 in March 2026, roughly 42% below its November peak, before doubling off that low.

The company is Neuland Laboratories Ltd, a Hyderabad based maker of active pharmaceutical ingredients rebuilt over the past decade around contract manufacturing for innovator drug firms. Market capitalisation is approximately Rs 29,064 crore, at the top edge of the small cap band. What follows covers what moved this custom synthesis stock, what CMS contributes, how concentrated the client base is, and what the regulatory record shows.

Click Here – Get Free Investment Predictions

How This Custom Synthesis Stock Performed Across Periods

The one year figure understates the volatility. Over six months this custom synthesis stock is up roughly 86%, because that window starts near the March 2026 bottom. Over one month it is slightly negative.

Period	Start close (Rs)	Return
1 Month (17 Aug 2026)	23,661	-3.4%
6 Months (17 Mar 2026)	12,273	+86.3%
1 Year (17 Sep 2025)	16,156	+41.5%
3 Years (18 Sep 2023)	3,684	+520.4%
5 Years (Sep 2021 week)	1,615	+1,315%

This custom synthesis stock was among the stronger names on a screen of NSE small cap stocks ranked by one year return, dated 17 September 2026. No split or bonus occurred in the window, so the gain is genuine price appreciation. Its 52 week range of Rs 11,500 to Rs 24,225 has a high more than double the low.

Why Did This Custom Synthesis Stock Rise 42% in a Year?

Earnings did the heavy lifting. Four dated events explain most of the move in this custom synthesis stock: September quarter profit tripling in November 2025, a record March quarter in May 2026, a tenfold jump in June quarter profit on 6 August 2026, and a commercial peptide module going live in September 2026.

November 2025: September Quarter Profit Triples

September 2025 quarter total income was Rs 516.1 crore, up 63.7% from Rs 315.2 crore. EBITDA rose 138.8% to about Rs 157 crore, the margin widening roughly 960 basis points to 30.4%, and net profit reached Rs 96.9 crore against Rs 32 crore, the first trigger for the custom synthesis stock. The custom synthesis stock traded near Rs 18,113 on 10 November 2025 and hit Rs 19,747 that week.

May 2026: A Record Quarter Lifts The Custom Synthesis Stock

The March 2026 quarter was the largest in company history: total income of Rs 788.7 crore, up about 135%, EBITDA of Rs 319.8 crore at a 41.2% margin, and net profit of Rs 212.7 crore. FY26 income crossed Rs 2,000 crore for the first time, at Rs 2,053 crore. The custom synthesis stock moved from Rs 15,003 on 30 April to Rs 17,666 by 8 May 2026.

5 and 6 August 2026: A Sterile API Deal and a Tenfold Profit Jump

On 5 August 2026 the company signed a long term contract manufacturing agreement with another listed Indian pharmaceutical firm for a dedicated sterile suite at a Visakhapatnam site, adding approximately 1,400 kg of annual sterile API capacity. The board also cleared a Rs 39.8 crore expansion at Bonthapally with Unit 1 already at 91% utilisation.

The next day brought June 2026 results: total income of Rs 650.1 crore, up 116.3%, and net profit of Rs 147.7 crore against Rs 13.9 crore, at a 36.1% operating margin. The custom synthesis stock gapped from Rs 19,956 on 5 August to Rs 21,543 on 6 August and Rs 22,855 on 7 August, roughly 15% in two sessions.

September 2026: The First Peptide Module Goes Commercial

In the week of 15 September 2026 the first module of a dedicated commercial peptide plant in Hyderabad was commissioned, a roughly 30 million dollar investment carrying 7,000 litres of reactor capacity, split between 750 litres solid phase and 6,250 litres liquid phase. It is module one of four. The custom synthesis stock hit its 52 week high of Rs 24,225 on 9 September 2026.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

Inside The CMS Business Behind This Custom Synthesis Stock

Contract manufacturing services, or CMS, is what makes this a custom synthesis stock rather than a commodity API play. CMS molecules are made exclusively for innovator clients under long term supply arrangements, at higher margins and longer contract life than generic sales. Alongside CMS sit Prime, the high volume older products, and Specialty, the complex ones.

In the nine months to December 2025, Specialty contributed roughly Rs 683 crore, Prime around Rs 355 crore and CMS about Rs 195 crore. By June 2026, commercial CMS projects were the stated driver of the 116% revenue jump. Management has flagged that this growth rests on roughly three molecules, with one more commercialisation due in FY27 and one or two in FY28.

Europe took about 53% of nine month revenue and North America 41%. Three US FDA compliant units around Hyderabad carry roughly 12,18,000 litres of reactor capacity, the base of this custom synthesis stock.

Neuland Labs Share Price And The Underlying Financials

Quarterly numbers in this custom synthesis stock swing hard, and anyone tracking the Neuland Labs share price has to accept that. June 2025 produced Rs 300.6 crore of revenue and Rs 13.9 crore of profit; March 2026 delivered Rs 788.7 crore and Rs 212.7 crore, because one CMS campaign can land inside a single quarter.

Quarter	Revenue (Rs cr)	EBITDA (Rs cr)	Operating margin	Net profit (Rs cr)
Jun 2025	300.6	42.4	14.5%	13.9
Sep 2025	516.1	157.3	30.6%	96.9
Dec 2025	447.8	85.2	19.4%	40.6
Mar 2026	788.7	319.8	41.2%	212.7
Jun 2026	650.1	231.4	36.1%	147.7

Annually the trend is cleaner. Revenue moved from Rs 1,200.9 crore in FY23 to Rs 1,571.1 crore in FY24, dipped to Rs 1,497.4 crore in FY25, then rose to Rs 2,053.2 crore in FY26. Net profit followed: Rs 163.5 crore, Rs 300.1 crore, Rs 260.1 crore, Rs 364 crore. That FY25 dip shows the custom synthesis stock does not compound in a line.

The balance sheet behind this custom synthesis stock is conservative: debt to equity 0.16, book value per share approximately Rs 1,460, return on equity 19.4%. FY26 operating cash flow of Rs 346.7 crore trailed capital expenditure of Rs 397.1 crore. The FY26 dividend was Rs 34.

Who Owns This Custom Synthesis Stock

Ownership of this custom synthesis stock has shifted towards institutions across five quarters, with domestic funds the buyers. Promoter holding has been flat near 32.6%, held mostly through a family trust.

Quarter	Promoters	FII	DII	Public
Jun 2025	32.68%	21.69%	11.57%	34.07%
Sep 2025	32.64%	20.60%	13.54%	33.21%
Dec 2025	32.63%	20.90%	14.71%	31.76%
Mar 2026	32.63%	20.46%	15.84%	31.07%
Jun 2026	32.62%	21.08%	16.51%	29.79%

Domestic institutional holding rose from 11.57% to 16.51% while the public float shrank from 34.07% to 29.79%. Foreign holding hovered near 21%, one fund at about 5.4% in June 2026, and a well known individual investor held 3.12%. That 32.6% promoter stake is low for a custom synthesis stock this size.

USFDA Inspections And The Compliance Record

Regulatory standing matters more for a custom synthesis stock than for most businesses, because an innovator client cannot move a validated molecule elsewhere. Unit 1 at Bonthapally, inspected from 18 to 22 March 2024, closed with zero Form 483 observations. Unit 2 at Pashamylaram, inspected from 28 April to 2 May 2025, drew one observation on facility management.

Unit 3 at Gaddapotharam received three Form 483 observations after an inspection from 22 to 26 May 2023, called minor and procedural by the company. It was inspected again from 10 to 14 August 2026, the outcome not confirmed in public disclosures at the time of writing. The new peptide plant sits inside an approved site.

Risks In This Custom Synthesis Stock

Customer concentration is extreme where it matters most. Disclosures for the nine months to December 2025 show the top five customers at 95% of CMS revenue and the top ten at 99%. Prime and Specialty are better spread, at 52% and 59% from the top five, but CMS carries the growth and margin in this custom synthesis stock. Losing one relationship would show up immediately.

Revenue is lumpy and margins may not hold. Operating margin ranged from 14.5% to 41.2% across five quarters. Management cites a long term EBITDA margin target of 25% and above, well below the 35.5% delivered in June 2026, attributing part of the strength to favourable exchange rates and mix. Reversion would reset expectations for the custom synthesis stock.

Valuation leaves little room for error. This custom synthesis stock trades at approximately 58.4 times trailing earnings against an industry figure near 37.4, on a price to book of about 15.5. Management has guided informally to around 20% growth for FY27 and FY28, far slower than the 116% print that drove the rerating.

Capital intensity is rising. Capital expenditure was Rs 397.1 crore in FY26, with Rs 121.6 crore more in the June quarter and roughly Rs 203 crore approved since. The four module peptide build out will absorb cash for years, depressing return on capital for this custom synthesis stock.

Liquidity and volatility are real constraints. This is a small cap trading above Rs 22,000 a share, with daily volumes often between 15,000 and 60,000 shares and several sessions this year swinging more than 8% intraday. Position sizing in this custom synthesis stock can itself move the price.

Regulatory and concentration risk compound. Because a few innovator clients drive CMS, an adverse inspection at the unit making those molecules would hit a disproportionate share of profit. No insolvency, restructuring, auditor qualification, renaming or significant promoter pledge has been reported, but the concentration risk is structural.

Download the Univest iOS App or Univest Android App to track the Neuland Labs share price live

Neuland Labs Share: Analyst View

Coverage is thin, normal at this size. A consensus compiled at end August 2026 across four broking firms carried a buy stance, with an average twelve month target of approximately Rs 24,335, a high of Rs 25,819 and a low of Rs 23,300. Against the 17 September 2026 close of Rs 22,860, that implies upside of roughly 6%, with the lowest target about 2% above the Neuland Labs share price.

Neuland Labs Share Price Target

Those are the only verified figures available, and the narrow spread suggests analysts see this custom synthesis stock as fairly priced after August. Any Neuland Labs share price target quoted today predates the September peptide commissioning. Price levels may help more near term: the 52 week high of Rs 24,225 is resistance, and Rs 19,000 to Rs 19,500, the late July base, is support.

A Neuland Labs share price target built from earnings would start with roughly 20% FY27 growth on a FY26 profit base of Rs 364 crore. Applying the current multiple lands close to where the Neuland Labs share price already trades. Further upside needs new molecule commercialisations, not multiple expansion.

Other Stocks to Track From the Same Return Screen

Beyond this custom synthesis stock, a screen of NSE small-cap stocks ranked by 1-year return also includes related names such as Suven Life Sciences with a 1-year return of 49.94%, Entero Healthcare at 48.61% and RR Kabel at 93.99%.

Among the names covered from that screen, MTAR Technologies returned 396.53% over one year. Readers can compare this custom synthesis stock with the Nifty 50 benchmark and track each of these names on Univest before making any decision.

Conclusion

The 42% one year gain in this custom synthesis stock came from a real step change in earnings. FY26 revenue crossed Rs 2,000 crore, June 2026 delivered a 36.1% operating margin, and the first commercial peptide module is live. The Neuland Labs share price has held most of that gain.

The offsetting facts are equally concrete. Five customers supply 95% of CMS revenue, three molecules carry commercial growth, margin has swung between 14.5% and 41.2% in five quarters, and the custom synthesis stock trades near 58 times trailing earnings against an industry figure around 37. Anyone weighing it underwrites a few client relationships and a long capital expenditure cycle.

Frequently Asked Questions

What is the 1 year return of Neuland Labs share price?

Ans. Neuland Labs share price rose approximately 42% between 17 September 2025 and 17 September 2026, from Rs 16,156 to Rs 22,860, with no split or bonus in the period.

Why did this custom synthesis stock rise so much in the last year?

Ans. Earnings growth drove almost all of it. Total income rose 63.7% in September 2025, about 135% in March 2026 and 116.3% in June 2026, with June quarter net profit of Rs 147.7 crore against Rs 13.9 crore.

What does the CMS business actually do?

Ans. CMS is contract manufacturing services, where the company makes active pharmaceutical ingredients exclusively for innovator drug firms under long term supply agreements, at higher margins and longer contract life than the generic lines.

How concentrated is the customer base?

Ans. Very concentrated in CMS. Disclosures for the nine months to December 2025 show the top five customers at 95% of CMS revenue and the top ten at 99%, and commercial CMS growth rests on roughly three molecules.

Has the company had any USFDA problems?

Ans. Nothing severe on the public record. Unit 1 cleared a March 2024 inspection with zero Form 483 observations, Unit 2 drew one observation in 2025 and Unit 3 three procedural observations in 2023. Unit 3 was re-inspected from 10 to 14 August 2026.

Is there a verified Neuland Labs share price target?

Ans. Yes, though coverage of this custom synthesis stock is thin. A consensus of four broking firms at end August 2026 showed an average twelve month target of approximately Rs 24,335, a high of Rs 25,819 and a low of Rs 23,300.

What are the main risks in this custom synthesis stock?

Ans. Customer concentration, lumpy revenue, margin normalisation and small cap liquidity are the four biggest. Operating margin ranged from 14.5% to 41.2% across five quarters, and the custom synthesis stock fell about 42% from its November 2025 high to its March 2026 low.

What is the current valuation of this custom synthesis stock?

Ans. This custom synthesis stock trades at approximately 58.4 times trailing earnings against an industry figure near 37.4, with price to book about 15.5 and return on equity of 19.4%. Market capitalisation is Rs 29,064 crore and debt to equity 0.16.